AR043603A1 - Composiciones inyectables para uso intramuscular conteniendo esteres de testosterona y un vehiculo que comprende aceite de ricino y un cosolvente - Google Patents

Composiciones inyectables para uso intramuscular conteniendo esteres de testosterona y un vehiculo que comprende aceite de ricino y un cosolvente

Info

Publication number
AR043603A1
AR043603A1 ARP040100843A ARP040100843A AR043603A1 AR 043603 A1 AR043603 A1 AR 043603A1 AR P040100843 A ARP040100843 A AR P040100843A AR P040100843 A ARP040100843 A AR P040100843A AR 043603 A1 AR043603 A1 AR 043603A1
Authority
AR
Argentina
Prior art keywords
testosterone
vehicle
esteres
water
injectable compositions
Prior art date
Application number
ARP040100843A
Other languages
English (en)
Inventor
Jan-Peter Ingwersen
Doris Hueler
Sabine Fricke
Wilhelm Kuhnz
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32748728&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR043603(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR043603A1 publication Critical patent/AR043603A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Composiciones farmacéuticas, formuladas para administración por inyección, que comprenden un éster de testosterona, en particular undecanoato de testosterona, en un vehículo que comprende aceite de ricino y un co-solvente. Al inyectar las composiciones de acuerdo con un esquema de administración particular, se obtienen niveles confiables de testosterona en suero, dentro del rango fisiológico normal, por un período prolongado. Esto permite el uso de las composiciones en terapias de reemplazo hormonal y en la anticoncepción masculina, sin el monitoreo concomitante de los niveles de testosterona en suero a cargo de un médico.
ARP040100843A 2003-03-14 2004-03-15 Composiciones inyectables para uso intramuscular conteniendo esteres de testosterona y un vehiculo que comprende aceite de ricino y un cosolvente AR043603A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200300399 2003-03-14

Publications (1)

Publication Number Publication Date
AR043603A1 true AR043603A1 (es) 2005-08-03

Family

ID=32748728

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100843A AR043603A1 (es) 2003-03-14 2004-03-15 Composiciones inyectables para uso intramuscular conteniendo esteres de testosterona y un vehiculo que comprende aceite de ricino y un cosolvente

Country Status (40)

Country Link
US (2) US7718640B2 (es)
EP (2) EP1457208B9 (es)
JP (1) JP4680891B2 (es)
KR (2) KR100882378B1 (es)
CN (2) CN101884639A (es)
AR (1) AR043603A1 (es)
AT (1) ATE336251T1 (es)
AU (1) AU2004218893B2 (es)
BR (2) BR122017008910A8 (es)
CA (1) CA2518910C (es)
CL (1) CL2004000527A1 (es)
CO (1) CO5700724A2 (es)
CR (1) CR7999A (es)
CY (1) CY1105794T1 (es)
DE (1) DE602004001893T2 (es)
DK (1) DK1457208T3 (es)
EA (1) EA011568B1 (es)
EC (1) ECSP056095A (es)
ES (1) ES2271772T3 (es)
HK (1) HK1069325A1 (es)
HR (1) HRP20050781B1 (es)
IL (1) IL170473A (es)
IS (1) IS2565B (es)
JO (1) JO2505B1 (es)
ME (2) MEP14508A (es)
MX (1) MXPA04002395A (es)
NO (1) NO335179B1 (es)
NZ (1) NZ542321A (es)
PE (1) PE20041065A1 (es)
PL (1) PL1457208T3 (es)
PT (1) PT1457208E (es)
RS (1) RS51537B (es)
RU (2) RU2354381C2 (es)
SA (1) SA04250040B1 (es)
SI (1) SI1457208T1 (es)
TW (1) TWI345976B (es)
UA (1) UA82510C2 (es)
UY (1) UY28231A1 (es)
WO (1) WO2004080383A2 (es)
ZA (2) ZA200508313B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
ES2930658T3 (es) 2005-04-15 2022-12-20 Tolmar Inc Sistemas de administración farmacéutica para medicamentos hidrofóbicos y composiciones que comprenden los mismos
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
EP2398461A1 (en) 2009-02-18 2011-12-28 Bayer Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20130178454A1 (en) * 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
EP2833944A4 (en) 2012-04-06 2016-05-25 Antares Pharma Inc ADMINISTRATION OF TESTOSTERONE COMPOSITIONS BY NEEDLE-SUPPORTED NOZZLE INJECTION
JP6055088B2 (ja) * 2012-05-09 2016-12-27 ウエスタン ユニバーシティ オブ ヘルス サイエンシズ プロリポソーム型テストステロン調合物
WO2014093818A2 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
EP2953667B1 (en) * 2013-02-11 2019-10-23 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
TW201521731A (zh) * 2013-03-15 2015-06-16 利波辛股份有限公司 用於口服之脂平衡的長鏈睪固酮酯
CN105744983B (zh) * 2013-08-12 2019-12-27 纳米医学***公司 用于缓释在增溶剂中的低水溶性治疗剂的装置和方法
CN106456704A (zh) 2014-04-16 2017-02-22 Veyx-药物有限公司 兽药组合物和其应用
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) * 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
CN105056115A (zh) * 2015-08-05 2015-11-18 成都市飞龙水处理技术研究所 一种治疗化脓性***的内服药物及其制备方法
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
US11311554B2 (en) 2018-04-04 2022-04-26 Slayback Pharma Llc Pharmaceutical compositions of testosterone
WO2020018974A1 (en) * 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
KR102051808B1 (ko) 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
CA3123301A1 (en) * 2018-12-14 2020-06-18 Acerus Biopharma Inc. Nasal pharmaceutical testosterone ester gel compositions for nasal administration and method
EP4038147A4 (en) * 2019-10-03 2024-02-07 Caren Pharmaceuticals, Inc. COMBINATORIAL HORMONAL THERAPIES AND FORMULATIONS
CA3184810A1 (en) * 2020-06-11 2021-12-16 Ash Stevens, Llc Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164520A (en) * 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4181721A (en) * 1975-10-27 1980-01-01 Schering Aktiengesellschaft Depot preparations in an oily, unsaturated solution for intramuscular injection
GB1567515A (en) 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
NL7711916A (nl) 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
US4242863A (en) * 1978-03-16 1981-01-06 Caterpillar Tractor Co. Dual phase fuel vaporizing combustor
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5364632A (en) * 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) * 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
CN1205921C (zh) * 1997-12-03 2005-06-15 麦克公司 含有氢化蓖麻油的长效注射制剂
AU756739B2 (en) 1998-06-19 2003-01-23 N.V. Organon Testosterone derivative
WO1999067270A1 (en) 1998-06-19 1999-12-29 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
ATE269708T1 (de) 1999-04-01 2004-07-15 Akzo Nobel Nv Formulierung enthaltend testosteonundecanoat und rizinusöl
CA2415349A1 (en) * 2000-08-23 2002-02-28 Akzo Nobel N.V. Testosterone ester formulation for human use

Also Published As

Publication number Publication date
ZA200700046B (en) 2008-04-30
NO20054711L (no) 2005-12-13
US20050032762A1 (en) 2005-02-10
KR100882378B1 (ko) 2009-02-05
HK1069325A1 (en) 2005-05-20
US7718640B2 (en) 2010-05-18
US8338395B2 (en) 2012-12-25
CN1761469A (zh) 2006-04-19
RU2354381C2 (ru) 2009-05-10
KR20050109561A (ko) 2005-11-21
RU2007118196A (ru) 2008-11-27
NZ542321A (en) 2008-05-30
DE602004001893D1 (de) 2006-09-28
CA2518910A1 (en) 2004-09-23
NO20054711D0 (no) 2005-10-13
CA2518910C (en) 2009-09-08
UA82510C2 (uk) 2008-04-25
SA04250040B1 (ar) 2008-01-07
TWI345976B (en) 2011-08-01
BR122017008910A2 (es) 2005-02-09
EP1743646A2 (en) 2007-01-17
MEP14508A (en) 2010-06-10
DE602004001893T2 (de) 2007-03-15
US20090156564A1 (en) 2009-06-18
ZA200508313B (en) 2007-04-25
PT1457208E (pt) 2007-01-31
AU2004218893B2 (en) 2008-10-09
ECSP056095A (es) 2006-03-01
TW200511997A (en) 2005-04-01
CO5700724A2 (es) 2006-11-30
ES2271772T3 (es) 2007-04-16
PE20041065A1 (es) 2005-02-24
ATE336251T1 (de) 2006-09-15
AU2004218893A1 (en) 2004-09-23
IS2565B (is) 2009-12-15
RS20050702A (en) 2007-06-04
KR20080096717A (ko) 2008-10-31
BRPI0400214A (pt) 2005-02-09
BR122017008910A8 (pt) 2023-05-09
CN1761469B (zh) 2019-05-17
HRP20050781B1 (hr) 2015-04-10
JP4680891B2 (ja) 2011-05-11
IS8069A (is) 2005-10-12
JP2006520377A (ja) 2006-09-07
WO2004080383B1 (en) 2005-05-06
MXPA04002395A (es) 2004-09-20
EP1457208A1 (en) 2004-09-15
EA200501819A1 (ru) 2006-06-30
IL170473A (en) 2010-05-31
CL2004000527A1 (es) 2005-02-18
HRP20050781A2 (en) 2005-10-31
JO2505B1 (en) 2009-10-05
EA011568B1 (ru) 2009-04-28
RS51537B (en) 2011-06-30
CN101884639A (zh) 2010-11-17
EP1743646A3 (en) 2007-03-28
NO335179B1 (no) 2014-10-13
EP1457208B1 (en) 2006-08-16
DK1457208T3 (da) 2006-12-11
PL1457208T3 (pl) 2007-01-31
BRPI0400214A8 (pt) 2023-05-09
EP1457208B9 (en) 2006-10-25
CY1105794T1 (el) 2011-02-02
ME00149B (me) 2010-06-10
WO2004080383A3 (en) 2005-03-31
WO2004080383A2 (en) 2004-09-23
RU2005131724A (ru) 2006-05-10
UY28231A1 (es) 2004-11-08
CR7999A (es) 2006-05-29
SI1457208T1 (sl) 2007-02-28

Similar Documents

Publication Publication Date Title
AR043603A1 (es) Composiciones inyectables para uso intramuscular conteniendo esteres de testosterona y un vehiculo que comprende aceite de ricino y un cosolvente
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
AR107285A2 (es) Vacuna
AR027510A1 (es) Formulacion
ECSP034654A (es) Productos de hormona esteroide y metodos para preparar los mismos
UY32327A (es) Antagonistas de receptores de ácido lisofosfatídico
AR033808A1 (es) Una composicion topica de anestesia local y los parches y los envases que la contienen
ES2185606T3 (es) Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
CL2009001059A1 (es) Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras.
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
CL2008002720A1 (es) Composicion farmaceutica transdermica para nebulizar, sin alcohol, que comprende uno o mas farmacos, los potenciadores de la penetracion transdermica eteres de dietilenglicol o filtros solares de ester, y liquidos no volatiles; dispositivo de dosificacion de nebulizacion medida que la comprende; metodo de fabricacion; y su uso.
PE20020348A1 (es) Exemestano como agente quimiopreventivo
UY27042A1 (es) Combinación de agonistas de gaba e inhibidores de sorbitol deshidrogenasa
PE20211588A1 (es) Compuestos y sus usos para aliviar sintomas asociados a la menopausia
PA8586201A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
GT200000166A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba.
BRPI0614197B8 (pt) composição farmaceuticamente eficaz em uma forma farmacêutica para administração peroral contendo pelo menos um dos ingredientes ativos indometacina e acemetacina, formas de administração, e, uso da composição
AR078393A1 (es) Inhibicion de la formacion de adhesiones en los tendones
DK1069912T3 (da) Injicerbare IGF-formuleringer, der indeholder succinat som puffermiddel
AR044831A1 (es) Forma de administracion inyectable de la flupirtina
CU23480B7 (es) Métodos y composiciones farmacéuticas para la obtención confiable de niveles aceptables de testosterona en suero
AR126239A1 (es) Región 5’ no traducida y región 3’ no traducida no naturales y uso de estas

Legal Events

Date Code Title Description
FC Refusal